Deciphera

Deciphera Pharmaceuticals is a chemical pharmaceutical company focused on the discovery, development, and commercialization of important new drugs to improve the lives of cancer patients. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple candidate products from our platform in clinical studies, QINLOCK® is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of gastrointestinal stromal tumor (GIST). Furthermore, QINLOCK is also approved as a fourth-line treatment for GIST in Australia, Canada, Hong Kong, and mainland China.